Wyeth’s fen/phen settlement Redux
Executive Summary
The firm announces May 24 that the so-called "Seventh Amendment" of the Redux settlement receives final judicial approval. The Seventh Amendment sets aside $1.275 bil. to fund less serious cases (1"The Pink Sheet" Feb. 7, 2005, In Brief). Wyeth has reserved $21 bil. for fen/phen claims and litigation, and has paid out an estimated $15.75 bil...
You may also be interested in...
Wyeth diet drug litigation
Wyeth increases Redux litigation reserve by $4.5 bil. ($2.6 bil. net of tax), bringing total fen/phen-related charges to $21.1 bil. Wyeth has paid $13.9 bil. in claims, leaving a balance of $7.2 bil. in reserve, as of Dec. 31. The charge assumes the so-called "Seventh Amendment" settlement will be accepted, although it still awaits final court approval. The Seventh Amendment would set aside $1.275 bil. to fund less serious cases (1"The Pink Sheet" Aug. 16, 2004, In Brief)...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.